The Mini-Addenbrooke's Cognitive Examination: A New Assessment Tool for Dementia

被引:185
作者
Hsieh, Sharpley [1 ,2 ,3 ,4 ]
McGrory, Sarah [5 ]
Leslie, Felicity [2 ]
Dawson, Kate [6 ]
Ahmed, Samrah [10 ]
Butler, Chris R. [10 ]
Rowe, James B. [6 ,8 ,9 ]
Mioshi, Eneida [7 ]
Hodges, John R. [2 ,3 ,4 ]
机构
[1] Univ New S Wales, Brain & Mind Res Inst, Sydney, NSW, Australia
[2] Univ New S Wales, Neurosci Res Australia, Sydney, NSW, Australia
[3] Univ New S Wales, ARC Ctr Excellence Cognit & Its Disorders, Sydney, NSW, Australia
[4] Univ New S Wales, Sch Med Sci, Sydney, NSW, Australia
[5] Univ Edinburgh, Dept Psychol, Alzheimer Scotland Dementia Res Ctr, Edinburgh, Midlothian, Scotland
[6] Univ Cambridge, Dept Clin Neurosci, Cambridge, England
[7] Univ Cambridge, Dept Psychiat, Cambridge, England
[8] Behav & Clin Neurosci Inst, Cambridge, England
[9] MRC, Cognit & Brain Sci Unit, Cambridge, England
[10] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford OX3 9DU, England
基金
澳大利亚国家健康与医学研究理事会; 澳大利亚研究理事会; 英国医学研究理事会;
关键词
Cognitive screening test; Frontotemporal dementia; Alzheimer's disease; Corticobasal degeneration; PRIMARY PROGRESSIVE APHASIA; ALZHEIMERS-DISEASE; DIAGNOSTIC-CRITERIA; BEHAVIORAL VARIANT; VALIDATION; MEMORY;
D O I
10.1159/000366040
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Aims: We developed and validated the Mini-Addenbrooke's Cognitive Examination (M-ACE) in dementia patients. Comparisons were also made with the Mini Mental State Examination (MMSE). Method: The M-ACE was developed using Mokken scaling analysis in 117 dementia patients [behavioural variant frontotemporal dementia (bvFTD), n = 25; primary progressive aphasia (PPA), n = 49; Alzheimer's disease (AD), n = 34; corticobasal syndrome (CBS), n = 9] and validated in an independent sample of 164 dementia patients (bvFTD, n = 23; PPA, n = 82; AD, n = 38; CBS, n = 21) and 78 controls, who also completed the MMSE. Results: The M-ACE consists of 5 items with a maximum score of 30. Two cut-offs were identified: (1) <= 25/30 has both high sensitivity and specificity, and (2) = 21/30 is almost certainly a score to have come from a dementia patient regardless of the clinical setting. The M-ACE is more sensitive than the MMSE and is less likely to have ceiling effects. Conclusion: The MACE is a brief and sensitive cognitive screening tool for dementia. Two cut-offs (25 or 21) are recommended. (C) 2014 S. Karger AG, Basel
引用
收藏
页码:1 / 11
页数:11
相关论文
共 32 条
[1]  
[Anonymous], INT PSYCHOGERIATR
[2]  
[Anonymous], DEMENT GEL LAB COGN
[3]  
[Anonymous], 2002, INTRODUCTION TO NONP
[4]  
[Anonymous], J STAT SOFTWARE
[5]  
Benson Aaron D, 2005, Prim Care Companion J Clin Psychiatry, V7, P62
[6]   Three-word recall in normal aging [J].
Chandler, MJ ;
Lacritz, LH ;
Cicerello, AR ;
Chapman, SB ;
Honig, LS ;
Weiner, MF ;
Cullum, CM .
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 2004, 26 (08) :1128-1133
[7]   Differentiation of semantic dementia and Alzheimer's disease using the Addenbrooke's Cognitive Examination (ACE) [J].
Davies, R. Rhys ;
Dawson, Kate ;
Mioshi, Eneida ;
Erzinclioglu, Sharon ;
Hodges, John R. .
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2008, 23 (04) :370-375
[8]   Validation of the Chinese Version of Addenbrooke's Cognitive Examination-Revised for Screening Mild Alzheimer's Disease and Mild Cognitive Impairment [J].
Fang, Rong ;
Wang, Gang ;
Huang, Yue ;
Zhuang, Jun-Peng ;
Tang, Hui-Dong ;
Wang, Ying ;
Deng, Yu-Lei ;
Xu, Wei ;
Chen, Sheng-Di ;
Ren, Ru-Jing .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2014, 37 (3-4) :223-231
[9]   Neuropsychological assessment of patients with dementing illness [J].
Fields, Julie A. ;
Ferman, Tanis J. ;
Boeve, Bradley F. ;
Smith, Glenn E. .
NATURE REVIEWS NEUROLOGY, 2011, 7 (12) :677-687
[10]   DISCRIMINATION BETWEEN STAGES OF ALZHEIMERS-DISEASE WITH SUBSETS OF MINI-MENTAL-STATE-EXAMINATION ITEMS - AN ANALYSIS OF CONSORTIUM TO ESTABLISH A REGISTRY FOR ALZHEIMERS-DISEASE DATA [J].
FILLENBAUM, GG ;
WILKINSON, WE ;
WELSH, KA ;
MOHS, RC .
ARCHIVES OF NEUROLOGY, 1994, 51 (09) :916-921